Article info

Download PDFPDF

Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease

Authors

  • Corrado Campochiaro Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  • Giulio Cavalli Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  • Nicola Farina Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  • Alessandro Tomelleri Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  • Giacomo De Luca Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  • Lorenzo Dagna Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Corrado Campochiaro, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, 20132 Milano, Italy; campochiaro.corrado{at}hsr.it
View Full Text

Citation

Campochiaro C, Cavalli G, Farina N, et al
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease

Publication history

  • Received November 7, 2019
  • Revised November 29, 2019
  • Accepted December 3, 2019
  • First published December 9, 2019.
Online issue publication 
January 04, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.